Daniel Tarditi, DO
Cardiovascular Disease · Haddon Heights, NJNPI 1386672467
Payments from drug & device makers
Across 606 payments — averaging $39.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Abbott$4K
- Novartis$844
- Impulse Dynamics (USA) Inc.$706
- Johnson & Johnson$624
- Boehringer Ingelheim$604
- plus $4K from 33 others
What the payments were for
- Consulting fees$4504%
- Food & beverage$11,85896%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 51 | $12,560 |
| Abbott | 147 | $4,435 |
| Novartis | 79 | $844 |
| Impulse Dynamics (USA) Inc. | 11 | $706 |
| Johnson & Johnson | 39 | $624 |
| Boehringer Ingelheim | 28 | $604 |
| AstraZeneca | 21 | $578 |
| Pfizer | 46 | $575 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 41 | $555 |
| Boston Scientific | 7 | $473 |
| Merck | 17 | $355 |
| E.r. Squibb & Sons, L.L.C. | 29 | $297 |
| Amarin Pharma, Inc. | 21 | $274 |
| Bayer | 11 | $208 |
| Esperion Therapeutics, Inc. | 10 | $143 |
| Medtronic | 2 | $140 |
| W. L. Gore & Associates, Inc. | 7 | $135 |
| Cvrx, Inc. | 3 | $84 |
| Regeneron Healthcare Solutions, Inc. | 5 | $73 |
| Sanofi-aventis U.S. LLC | 5 | $63 |
| Scpharmaceuticals Inc. | 3 | $49 |
| Edwards Lifesciences | 1 | $49 |
| Novo Nordisk | 3 | $46 |
| Astellas Pharma US Inc | 3 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Heartflow, Inc. | 1 | $23 |
| Acarix USA Inc. | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $18 |
| Regeneron | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$900
- Confirm Rx$339
- AVEIR$333
- AMPLATZER$285
- Fortify Assura, Ellipse ICD$242
- JARDIANCE$229
- VERQUVO$206
- Fortify Assura$149
- WATCHMAN FLX$146
- HeartMate$144
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$123
- Watchman$121
- Pipeline$117
- CAMZYOS$108
How this compares
$24,178 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 354 | $459,621 |
| XareltoRivaroxaban | 143 | $200,931 |
| Repatha SureclickEvolocumab | 66 | $85,934 |
| FarxigaDapagliflozin Propanediol | 49 | $70,425 |
| EntrestoSacubitril/Valsartan | 43 | $63,343 |
| OzempicSemaglutide | 32 | $57,887 |
| JardianceEmpagliflozin | 19 | $28,761 |
| Praluent PenAlirocumab | 15 | $20,097 |
| Carvedilol ErCarvedilol Phosphate | 17 | $10,516 |
| Metoprolol Succinate | 491 | $7,579 |
| Atorvastatin Calcium | 490 | $5,940 |
| Ezetimibe | 168 | $4,630 |
| Rosuvastatin Calcium | 305 | $4,349 |
| Candesartan Cilexetil | 25 | $4,177 |
| Flecainide Acetate | 55 | $3,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $575 | $459,621354 claims |
| Johnson & JohnsonXarelto | $624 | $200,931143 claims |
| AstraZenecaFarxiga | $578 | $70,42549 claims |
| NovartisEntresto | $844 | $63,34343 claims |
| Novo NordiskOzempic | $46 | $57,88732 claims |
| Boehringer IngelheimJardiance | $604 | $28,76119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Haddon Heights
- Mark GelerntHaddon Heights$2M
- Dilip ViswanathHaddon Heights$1.8M
- Sanford GipsHaddon Heights$668K
- Andreas PavlidesHaddon Heights$598K
- Vijayendra VermaHaddon Heights$359K
- Harvey SnyderHaddon Heights$93K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Robert FishbergSpringfield$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.